SO

Stephen Opat

Mutual Connections
Loading...
S9-052025-1213934

Send Message

No file chosen
2 Publications
0 Followers
0 Following
0 Questions

👤 About

Skills & Expertise

No skills added yet.

Research Interests

No research interests added yet.

Connect With Me

📚 Publications (2)

Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program
Journal: Leukemia & Lymphoma • November 2022
Ibrutinib is a small molecule inhibitor of Bruton’s tyrosine kinase indicated for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and m...
Chronic lymphocytic leukemia Mantle cell leukemia Real-world Ibrutinib
Indolent lymphoma: addressing the needs of survivors
Journal: Leukemia & Lymphoma • January 2025
Over the past two decades, there has been a continuous improvement in outcome for patients with indolent lymphoma (iNHL) resulting in a gradual accumulation of survivors. While life expectancy in the...
Survivorship care Lymphoplasmacytic lymphoma Waldenström’s macroglobulinemia Marginal zone lymphoma Follicular lymphoma Cll Chronic lymphocytic leukemia Indolent lymphoma
dd